Status:
UNKNOWN
cfDNA Methylation Assay for Clinical Evaluation of Patients With Stage IA Lung Cancer After Ablation Operation
Lead Sponsor:
Shanghai Chest Hospital
Conditions:
Lung Cancer
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
The objective is to screen and monitor the efficacy of cfDNA methylation in patients with stage I lung cancer after ablation, to compare the similarities and differences of cfDNA methylation between s...
Detailed Description
The objective is to screen and monitor the efficacy of cfDNA methylation in patients with stage I lung cancer after ablation, to compare the similarities and differences of cfDNA methylation between s...
Eligibility Criteria
Inclusion
- Age: 18-85 years old;
- The peripheral pulmonary nodules found in patients with chest CT, preoperative examination showed that the clinical stage of patients was T1N0M0, IA;
- patients are not suitable for surgical treatment through multidisciplinary assessment, agree to accept ablation
- Patients have good compliance with the tests and follow-ups, understand the situation of the study and sign informed consent.
Exclusion
- The patient is generally in poor condition and cannot tolerate the examination;
- patients with a cardiac pacemaker or stent in the heart; peripheral tumors of the lungs are adjacent to large blood vessels or important structures;
- patients with poor compliance;
- Researchers believe that it is not appropriate to participate in this trial.
Key Trial Info
Start Date :
June 17 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 17 2021
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04413656
Start Date
June 17 2019
End Date
June 17 2021
Last Update
June 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China, 200030